Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 40
Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 121
Unifeye Vision Partners Expands Further into Texas
Dallas, Texas-based Unifeye Vision Partners (UVP) announced on September 25 its acquisition of Sweeney Eye Associates. The financial terms were not disclosed. Sweeney Eye Associates is an ophthalmology practice with two locations in the Dallas, Texas MSA. It provides services out of its clinic and ambulatory surgery center. According to its website, it has six physicians on staff. UVP, a portfolio company of private equity firm Waud Capital Partners, is a network of eye care providers. The company provides management and support services to ophthalmology and optometry practices as well as single-specialty eye surgery centers. UVP extends its operations to a network of more than... Read More »
Alfasigma Acquires Intercept Pharmaceuticals
Alfasigma S.p.A announced on September 25 that it acquired Intercept Pharmaceuticals for more than $793.87 million. According to data captured in the LevinPro HC database, this transaction represents the 81st Pharmaceutical acquisition of the year. Intercept Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, including primary biliary cholangitis and severe alcohol-associated hepatitis. The company announced revenues of $285.71 million for the full year ending on December 31, 2022. One of Intercept’s lead products is Ocaliva®, which is the only FDA-approved... Read More »
SOHM Acquires ABBIE
On September 25, SOHM, Inc. announced that it acquired ABBIE from CGA 369 for $10 million. ABBIE is a gene-editing platform which can deliver genetic payloads using non-viral vectors. ABBIE uses targeted integration to insert larger DNA sequences, including full genes, into a desired loci of the target cell’s genome. ABBIE will be able to edit genes of a large number of cell types at different stages of their life cycles, overcoming the limitations of current cell editing and cell engineering technologies. SOHM, is a generic pharmaceutical manufacturing and marketing company with a vision of “Globalè Prospèro” that tries to build continuous growth. SOHM’s... Read More »
Enovis Corporation Acquires LimaCorporate
Stockholm-based private equity firm, EQT AB, announced on September 25 that it was selling LimaCorporate to Enovis Corporation. LimaCorporate is a global orthopedic implant manufacturer with a reputation for innovation, reflected in its industry leading know-how in additive manufacturing, such as its proprietary Trabecular Titanium technology. The company focuses on shoulder, knee and hip prostheses with a portfolio that includes one of the first modular shoulder systems in the world, the SMR, the Delta hip cup family and the Physica system knee. According to its financial report, it generated revenue of more than $263.75 million in 2022. Enovis Corporation is a... Read More »
Ascend Partners’ Portfolio Company Acquires Metzger Comprehensive Care
On September 25, Medical Specialists of the Palm Beaches (MSPB) announced its acquisition of a one-physician practice: Metzger Comprehensive Care. Metzger Comprehensive Care is a concierge medicine practice in Boca Raton, Florida. The practice is run by Dr. Charles Metzger. Backed by Ascend Partners, MSPB is a primary care-focused, multi-specialty physician group practice in South Florida. It has a team of more than 95 providers and more than 35 offices across the state. This transaction is MSPB’s third acquisition in 2023 and adds to MSPB’s concierge services. The financial terms of the acquisition were not disclosed. According to data captured in... Read More »
Flourish Research Acquires Valley Clinical Trials
Flourish Research, backed by private equity firm NMS Capital, announced its acquisition of Valley Clinical Trials, based in the Los Angeles suburb of Northridge, California. The financial terms of the transaction were not disclosed. Valley Clinical Trials is a leading clinical research site with three locations in California that specialize in cardiology, metabolic and related therapeutic areas. Since its founding in 2010, Valley has rapidly grown into a leading multi-site clinical trials company serving a broad and diverse population of patients in Los Angeles County. Launched in 2021. Flourish Research is a clinical trial site network. The company has sites throughout... Read More »
The Dermatology Specialists Acquires Delaware Valley Dermatology
The Dermatology Specialists, based in New York City, announced its acquisition of Wilmington, Delaware-based Delaware Valley Dermatology. Led by Dr. Michael Saruk, MD, FAAD, Delaware Valley Dermatology has been providing dermatologic care for more than two decades. Dr. Saruk, according to the practice’s website, is supported by a staff of two employees. The Dermatology Specialists was established in 2019 and has since grown to become one of the largest dermatology groups in New York City. With more than 100 providers. The company cares for more than 500,000 patients each year out of more than 40 locations. It offers a comprehensive range of medical, cosmetic... Read More »
Murphy Canyon Acquisition Corp. Merges with Conduit Pharmaceuticals
Murphy Canyon Acquisition Corp. (MURF) announced on September 22 the completion of its previously announced merger with Conduit Pharmaceuticals Inc. for a pro forma enterprise value of approximately $720 million. According to data captured in the LevinPro HC database, this transaction represents the 79th Pharmaceuticals transaction of the year. Conduit is a disease agnostic life science company providing an efficient model for compound development. Conduit acquires assets that are Phase II-ready and then seeks an exit through third-party license deals following successful clinical trials. Led by a team of pharmaceutical executives, it was established to fund the development of... Read More »
Shore Capital-Backed SENTA Partners Acquires Advanced ENT and Allergy
Southern Ear Nose Throat & Allergy (SENTA) Partners, a portfolio company of private equity firm Shore Capital Partners, has announced a new partnership with Advanced ENT and Allergy, with locations in Kentucky and Indiana. Advanced ENT and Allergy is a leading ear, throat & nose (ENT) and allergy practice in the Southern United States, with nearly 170 employees across six locations. According to its website, there are 14 physicians on staff. Founded in 2019, SENTA Partners is an ENT and allergy management services organization with more than 930 employees, including 180 providers across 66 locations in seven states. This partnership further solidifies SENTA’s... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
